Last reviewed · How we verify
Amolin
At a glance
| Generic name | Amolin |
|---|---|
| Also known as | Amoxicillin |
| Sponsor | Chang Gung Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacies of Hybrid and High-dose Dual Therapies for the First-line Anti-H Pylori Treatment (NA)
- Dexlansoprazole MR-Based Concomitant Quadruple Therapy (NA)
- Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy (NA)
- Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication (NA)
- The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amolin CI brief — competitive landscape report
- Amolin updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI